New add-on treatment to insulin for treatment of certain patients with type 1 diabetes

March 1, 2019 – EMA’s human medicines committee (CHMP) has adopted a positive opinion for sotagliflozin intended as an adjunct to insulin for certain patients with type 1 diabetes mellitus. Sotagliflozin is a small molecule with dual inhibitor activity on SGLT1 and SGLT2. It works in the kidneys to prevent reabsorption of glucose from the urine and in the proximal intestine to delay and reduce glucose absorption into the blood stream, which helps lower the blood … (leggi tutto)